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Abstract: Abnormal blood glucose (BG) concentrations have been associated with negative outcomes in 
critically ill adults and infants. Diagnosis of hyperglycaemia and hypoglycaemia is by BG measurements, 
which are typically taken several hours apart due to the clinical effort required. Continuous glucose 
monitoring (CGM) devices, which take measurements every 5 minutes, have the potential to improve the 
detection and diagnosis of these glycaemic abnormalities. There have been relatively few successful 
investigations of CGM devices in the ICU, and one study reported significant sensor noise. If CGM 
devices are going to be used in the clinical setting to monitor, diagnose and potentially treat critical 
illness, clinicians need to know data are reliable and accurate. This study uses CGM data from neonatal 
infants to develop a tool that will aid clinicians in identifying unusual CGM behaviour. A stochastic 
model was created to classify CGM measurements with the aim of highlighting unusual CGM behaviour. 
In addition, the method uses a colour coded CGM trace to convey the information quickly and efficiently, 
either retrospectively or in real-time. The method has been used to detect unusual hypoglycaemic events 
and potential sensor degradation, both of which need to be interpreted with care. Overall, while BG 
measurements are required to make definitive conclusions about glycaemic events, the stochastic model 
provides another level of information to aid users in interpretation and decision making. 
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1. INTRODUCTION 
Abnormal blood glucose (BG) concentrations have been 
associated with increased morbidity and mortality in both 
critically ill adults and infants. Patients in the intensive care 
unit (ICU) often experience high levels of insulin resistance 
and stress-induced hyperglycaemia, which can negatively 
impact outcomes (Capes et al., 2000, Finney et al., 2003, 
Krinsley, 2003, Bistrian, 2001, Van den Berghe et al., 2001). 
Further complicating the matter, hypoglycaemia and 
glycaemic variability have both been independently linked to 
mortality in critically ill patients (Egi et al., 2006, Egi et al., 
2010, Hermanides et al., 2010, Krinsley, 2008). 
Diagnosis of hyperglycaemia and hypoglycaemia in critically 
ill patients is by blood glucose (BG) measurements, which 
are typically taken several hours apart.  More frequent BG 
measurements are not clinically practical due to the 
additional nursing workload (Carayon and Gurses, 2005, 
Chase et al., 2008, Mackenzie et al., 2005) and consequently, 
important glycaemic events between BG measurements can 
go undetected. Continuous Glucose Monitoring (CGM) 
devices have the potential to improve the detection and 
diagnosis of these glycaemic abnormalities. The continuous 
glucose monitoring system (CGMS® System Gold™ 
Medtronic, Minimed, Northridge, CA, USA) provides a 
glucose value every 5 minutes or 288 measurements per day, 
with only 4 BG measurements per day required for device 
calibration. 
There have been relatively few successful investigations of 
CGMs in critical care use (Goldberg et al., 2004), although 
they are well studied in Type 1 diabetes (Breton and 
Kovatchev, 2008, Klonoff, 2005a, Klonoff, 2005b). In 
particular, one set of tight glycaemic control trials using 
CGM technology was not particularly successful due, in part, 
to significant sensor noise (Chee et al., 2003a, Chee et al., 
2003b). Added sensor noise is a trade off (in some cases) for 
the CGMs far higher, automated sampling rate (Goldberg et 
al., 2004, Clarke et al., 2005) and must be effectively 
managed for these devices to be used successfully. However, 
these sensor and algorithm technologies are also constantly 
evolving with every new generation offering improvements 
(Klonoff, 2005b, Skyler, 2009). 
If CGM devices are going to be used in the clinical setting to 
monitor, diagnose and potentially treat critical illness, 
clinicians need to know the data is reliable and accurate. 
Consider a scenario in which CGM data are retrospectively 
analysed to classify hypoglycaemia in neonates, where 
frequent BG measurements are not available. Three 
consecutive measurements in a CGM trace read 4mmol/L, 
2.5mmol/L, followed by 4mmol/L. If hypoglycaemia was 
classified as a measurement below 2.6mmol/L, then this 
  
     
 
would be recorded as a hypoglycaemic event. However, if the 
rest of the CGM trace was very stable with low variability, 
intuition would suggest this 'event' is potentially a sensor 
artefact.  
Our manuscript describes a tool that will aid clinicians in 
identifying unusual CGM behaviour, retrospectively or in 
real-time, and highlight sections of the CGM glucose trace 
that potentially need to be interpreted with care.   
2. SUBJECTS AND METHODS 
2.1  Subjects 
This study uses CGM data from 50 babies at risk of 
hypoglycaemia who were admitted to the Waikato Hospital 
Newborn Intensive Care Unit (NICU). Table 1 presents the 
cohort demographics for the 50 patients. Demographics are 
presented as median [interquartile range] where applicable. 
Table 1: Patient demographics 
Cohort Demographics
Number of CGM traces 50
Sex (M/F) 26/24
Gestational Age (weeks) 34 [33 - 37]
Birthweight (g) 2172 [1880 - 2990]
Primary Risk (# infants):
Diabetes 15
Premature 19
Small or Large for gestational age 14
Other 2  
2.2  Continuous Glucose Monitoring 
All patients had interstitial glucose monitoring using the 
CGMS® System Gold™. Monitoring began on admission to 
the NICU and finished after 7 days or earlier if the baby was 
no longer considered at risk of hypoglycaemia. During the 
monitoring period nurses were asked to record all blood 
glucose concentrations, feeding and medication for the 
management of hypoglycaemia. However, they remained 
blind to the glucose concentrations determined by the device. 
The device was calibrated as per the manufacturer’s 
recommendations and all of the data entered into the device 
were checked against clinical records for accuracy. Upon 
completion of continuous glucose monitoring, data were 
downloaded to a PC using CGMS system solutions software 
version 3.0C, which calibrated the CGM readings 
retrospectively. 
2.3  Calibration Measurements 
All BG calibration measurements were determined by a 
blood gas analyser (Radiometer, ABL800Flex, Copenhagen) 
using the glucose oxidase method. This device has a reading 
range of 0.0 to 60.0mmol/L and a coefficient of variation of 
2.1% (Harris et al., 2010). Due to the location of the blood 
gas analyser, a short time delay (estimated < 25mins 
maximum) was possible between taking the blood sample 
and entering the calibration glucose level into the device. 
2.4  Stochastic Model and CGM Classification 
A stochastic model based on the kernel density method was 
used to classify CGM measurements as expected or 
unexpected, using the previous CGM measurement and 
information about the history of CGM behaviour. The model 
is an extension to the methods described by Lin et al (Lin et 
al., 2008) who developed a stochastic model for insulin 
sensitivity prediction. 
The CGM data sets are broken down into paired, consecutive 
CGM measurements (CGMn-1, CGMn). Kernel density 
estimation methods are used to create a smooth, continuous, 
non-parametric model surface that reflects the data pattern. 
For every possible CGMn-1, the stochastic model provides a 
continuous, empirical estimate of the conditional probability 
density function (pdf) for the next CGM measurement, 
CGMn. These conditional pdf’s provide the basis for 
classifying CGM measurements and identifying unusual 
CGM behaviour.  
Using the stochastic model, a given CGM measurement, 
CGMn, would be classified as follows:  
1. The previous measurement, CGMn-1, is used to find 
the corresponding conditional pdf from the model.  
2. CGMn is located in the pdf and its percentile value 
in the conditional pdf is determined.  
3. The percentile is used to classify CGMn, where a 
very high or very low percentile is indicative of an 
outlier. These outliers are classified as unusual 
CGM measurements. 
The measurement-to-measurement sections of the CGM trace 
were colour coded based on the percentile value, to highlight 
areas of unusual CGM behaviour quickly and effectively. 
Three confidence intervals (CI’s) were used to specify the 
colour: within 80% CI (10
th
-90
th
 percentile) was blue, within 
90% CI (5
th
-95
th
 percentile) was cyan, within 99% CI (0.5
th
-
99.5
th
 percentile) was yellow, and outside 99% CI was red. 
These intervals were chosen based on the data used in this 
study and can be customised for different patient groups 
and/or different CGM sensors. As the scale starts at 80% CI, 
the focus here is on classifying outliers, rather than the full 
range. 
3. RESULTS 
Figure 1 shows a plot all of the CGM data (CGMn-1, CGMn). 
The contour lines represent the 5th, 25th, 50th, 75th, and 95th 
percentiles of the stochastic model surface. Figure 2 shows a 
distribution of the data density by glycaemic level. Figure 3 
shows a surface plot of the stochastic model. Conditional 
probability density functions are slices parallel to the CGMn 
axis, and each slice has an area under the curve of 1.0. Figure 
4 shows a comparison of the pdf's obtained from the model 
versus the pdf's obtained directly from the CGM data. Each 
pdf shows the expected distribution of CGMn given a 
  
     
 
previous measurement (CGMn-1) of 2, 4, 6, 8 or 10mmol/L. It 
should be noted that the pdf's could be generated for any 
value of CGMn-1 within the bounds of the model; Figure 4 
shows just five examples.  
Figures 5-7 show three examples of CGM traces that have 
been coloured using the stochastic classification method. 
Figure 5 shows a stable trace, which is almost entirely dark 
blue, indicating the measurement-to-measurement change 
 
 
 
 
Figure 1: Plot of CGM measurement pairs (CGMn-1, CGMn) 
with contour lines representing the 5
th
 to 95
th
 percentiles, 
from the bottom of the plot up. 
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Figure 2: Density of the data set by glycaemic level. Density 
is shown as a percent of the total data set (67,438 
measurements). 
throughout the trace is not unusual. Figure 6 shows a trace 
with several potentially unusual measurements throughout 
the trace. The hypoglycaemic event that occurs at 
approximately one day after monitoring began is coloured red 
and classified as very unusual. Figure 7 shows a trace with a 
few potentially unusual measurements for the first three days 
of monitoring. After day 3 a high proportion of the CGM 
measurements are classified as very unusual and are coloured 
red. 
 
 
 
 
 
Figure 3: Stochastic model surface for this data set 
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Figure 4: Comparison of conditional probability density 
functions at different CGMn-1. Pdf's from the model are solid 
lines and empirical pdf's from actual CGM data are dotted
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Figure 5: Stable CGM trace with no yellow or red measurements indicating no CGM measurements were classified unusual. 
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Figure 6: CGM trace with several measurements classified as mildly unusual. Note the hypoglycaemic event at ~1 day which 
has been classified as very unusual (red). 
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Figure 7: CGM trace with several measurements classified as mildly unusual. After day 3 the trace is classified as very 
unusual (red) and could be indicative of sensor malfunction. 
Very unusual 
behaviour 
Very unusual 
behaviour 
  
     
 
4. DISCUSSION 
The aim of this study was to design a tool that could aid 
clinicians in identifying unusual CGM behaviour that should 
potentially be interpreted with care. Stochastic modelling 
methods from (Lin et al., 2008) and a method of colouring 
CGM traces were used to highlight unusual CGM behaviour 
clearly and efficiently, in either real-time or retrospectively. 
Figures 1 and 2 give information about the raw data used to 
create the stochastic model. More than 99% of the data is 
within 2-10mmol/L range, shown in Figure 2. There are 
several outliers in Figure 1 that have a very large change in 
glycaemia over the 5 minute measurement interval. The high 
data density means these outliers have little effect on the 
model fit, shown by the smooth and tight percentile lines in 
Figure 1. However, below 2mmol/L there are 97 CGM 
measurements and due to the relatively low density of data 
the outliers have more impact on the model fit. This effect is 
shown by the 95th percentile line of the model, which strays 
upward at levels below 2mmol/L. Similarly, above 
10mmol/L there are only 232 measurements and the 
percentile lines all have a wave-like shape, again showing the 
effect of outliers where data density is low. A greater data 
density would alleviate these issues without changing the 
approach in this proof-of-concept. 
Figure 3 shows the surface of the stochastic model. The 
colour gradient shows how the shape of the model changes in 
the domain of CGMn-1 and that a single, global probability 
density function is not applicable to this data set. Figure 4 
further reinforces this with 5 pdf’s taken from the model at 
different CGMn-1 values, resulting in 5 different shaped 
density functions. These pdf’s are also used to show that the 
model fits the empirical data well. The model pdf’s (solid 
lines) overlay the empirical data (dotted lines) with only 
minor discrepancies.  
Figures 5-7 show 3 different CGM data sets and how the 
stochastic model classified the individual CGM 
measurements within them. Figure 5 shows a very stable, flat 
CGM trace with only small variations over the 3.5 days of 
monitoring. The CGM trace passes near all calibration 
measurements and there doesn’t appear to be any unusual 
CGM behaviour. The stochastic model classified almost the 
entire trace as dark blue indicating no unusual CGM 
behaviour. The interpretation of this trace would not likely be 
influenced with the additional information provided by the 
model. 
Figure 6 shows a less stable CGM trace with a lot more 
variability. This trace contains a few yellow and red sections 
that potentially need to be interpreted with care. The focus of 
this discussion is the hypoglycaemic event that occurs at 
~day 1. In the sequence of 5 measurements that lead up to the 
1.8mmol/L minimum, there are two drops of ~1mmol/L per 5 
minute measurement interval. The model has determined 
these are extreme outliers and consequently they have been 
coloured red. The trace then rises to above 4mmol/L in 5 
measurements, similarly with two rises of ~1mmol/L per 5 
minute measurement interval. Although the physiological 
limits of glucose rate-of-change are still unknown, the level 
of sensor error that has been reported in previous CGM 
studies (Breton and Kovatchev, 2008, Goldberg et al., 2004) 
suggest that this hypoglycaemic event could potentially be 
either glycaemia or sensor error.  
It is important to note that the aim of the stochastic model 
presented is not to try and determine the cause of the drop in 
CGM glucose, but rather to highlight the fact it should be 
interpreted with care. Furthermore, if the stochastic model 
was implemented in a real-time clinical setting and the 
downward CGM measurements were observed, it would be 
beneficial for the clinician to know whether the sequence of 
measurements is typical of CGM devices and that patient 
cohort. It should also be noted that without an accurate BG 
measurement at ~1 day, no exact conclusion can be drawn 
about the whether the hypoglycaemic event in this data was 
due to sensor error, or a true glycaemic event. 
However, this lack of confirmation is often the reality with 
CGMs. Clinical protocols might use stochastic information to 
justify an added calibration measurement to clarify a 
potentially significant event. After an event, such traces 
would yield insight not present at the bedside.  
Figure 7 shows an example of CGM data that becomes 
increasingly more variable and unstable at approximately day 
3 of monitoring. Before day 3, the CGM trace is 
predominantly blue and cyan with only small patches of 
yellow and occasionally red. However, after day the 3 the 
CGM trace is almost entirely red indicating the stochastic 
model has classified these measurements as very unusual. 
The sudden apparent degradation of reliable CGM 
measurements could be due to a sensor failure. This is not an 
unreasonable hypothesis, given the sensors used in this study 
were validated for 3 days of continuous monitoring. Again, 
without more frequent, accurate BG measurements during the 
period after day 3 no definitive conclusions can be drawn. 
However, this example represents another potential use of 
this stochastic model classification method that might be 
useful to users of CGM devices.  
5.  CONCLUSIONS 
This study has produced a stochastic model capable of 
classifying CGM measurements with the aim of highlighting 
unusual CGM behaviour. The method uses a colour coded 
CGM trace to convey the information quickly and efficiently 
and it is computationally light enough to be used 
retrospectively or in real-time. 
There are several potential uses for the stochastic 
classification which include, but are not limited to, 
classification of hypoglycaemia and detection of potential 
sensor failure. Equally, they can augment alarming methods 
or be used to more optimally time BG measurements in 
cohorts, such as neonates, where blood draws are restricted. 
Overall, while BG measurements are required to make 
definitive conclusions about glycaemic events, the stochastic 
model provides another level of information to aid users in 
interpretation and decision making. 
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